Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a fairly new class of treatment for diabetes mellitus. Some data suggest SGLT2 inhibitors are associated with a risk of severe urinary tract infections. However, meta-analyses of trials and a large population-based cohort study show no increased risk, which provides important reassurance for patients and prescribers.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19
Endocrine Open Access 06 March 2024
-
Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study
Critical Care Open Access 16 May 2023
-
Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application
Pflügers Archiv - European Journal of Physiology Open Access 07 August 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Zelniker, T. A. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393, 31–39 (2019).
Food and Drug Administration. Postmarket drug safety information for patients and providers: sodium-glucose cotransporter-2 (SGLT2) inhibitors. FDA https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/sodium-glucose-cotransporter-2-sglt2-inhibitors (2019).
Hirji, I. et al. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J. Diabetes Complications 26, 513–516 (2012).
Schneeberger, C., Holleman, F. & Geerlings, S. E. Febrile urinary tract infections: pyelonephritis and urosepsis. Curr. Opin. Infect. Dis. 29, 80–85 (2016).
Puckrin, R. et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 55, 503–514 (2018).
Radholm, K. et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - a systematic review. Diabetes Res. Clin. Pract. 140, 118–128 (2018).
Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357 (2018).
Bersoff-Matcha, S. J. et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors a review of spontaneous postmarketing cases. Ann. Intern. Med. 170, 764–769 (2019).
Dave, C. V. et al Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann. Intern. Med. 171, 248–256 (2019).
Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
JW has undertaken consultancy work and given lectures on behalf of Astellas, AstraZeneca, Boehringer Ingelheim, Janssen, Merck Sharpe and Dohme, all of whom produce SGLT2 inhibitors. JW has been an investigator for several SGLT2 inhibitor trials and was a member of the DECLARE TIMI-58 trial steering committee. JW has also undertaken consultancy, undertaken clinical trials and given lectures on behalf of companies that produce other treatments for diabetes mellitus, namely Novo Nordisk, Eli Lilly, Sanofi and Takeda. JW received renumeration for time spent as a consultant and time spent on clinical trials via his employing institution, the University of Liverpool.
Rights and permissions
About this article
Cite this article
Wilding, J. SGLT2 inhibitors and urinary tract infections. Nat Rev Endocrinol 15, 687–688 (2019). https://doi.org/10.1038/s41574-019-0275-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-019-0275-6
This article is cited by
-
Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19
Endocrine (2024)
-
Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study
Critical Care (2023)
-
Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD
Pediatric Nephrology (2022)
-
SGLT2i: beyond the glucose-lowering effect
Cardiovascular Diabetology (2020)
-
Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application
Pflügers Archiv - European Journal of Physiology (2020)